Nab-Paclitaxel as new Therapeutic Option for Pancreatic Cancer

被引：0
|
作者：
Michl, P. [1 ]
机构：
[1] Univ Marburg, Klin Gastroenterol Endokrinol & Stoffwechsel, D-35043 Marburg, Germany
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2013年 / 51卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
下载
收藏
页码：1329 / 1330
页数：2
相关论文
共 50 条
  • [41] A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
    Andrew H. Ko
    Thach-Giao Truong
    Emily Kantoff
    Kimberly A. Jones
    Elizabeth Dito
    Anna Ong
    Margaret A. Tempero
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 875 - 881
  • [42] Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer
    Muranaka, Tetsuhito
    Kuwatani, Masaki
    Komatsu, Yoshito
    Sawada, Kentaro
    Nakatsumi, Hiroshi
    Kawamoto, Yasuyuki
    Yuki, Satoshi
    Kubota, Yoshimasa
    Kubo, Kimitoshi
    Kawahata, Shuhei
    Kawakubo, Kazumichi
    Kawakami, Hiroshi
    Sakamoto, Naoya
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 8 (03) : 566 - 571
  • [43] Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines
    Braun, Lukas M.
    Lagies, Simon
    Guenzle, Jessica
    Fichtner-Feigl, Stefan
    Wittel, Uwe A.
    Kammerer, Bernd
    CELLS, 2020, 9 (05)
  • [44] Dosing Schedules of Gemcitabine and nab-Paclitaxel for Older Adults With Metastatic Pancreatic Cancer
    Winer, Arthur
    Handorf, Elizabeth
    Dotan, Efrat
    JNCI CANCER SPECTRUM, 2021, 5 (05)
  • [45] Survival of patients with advanced pancreatic cancer is increased by nab-paclitaxel plus gemcitabine
    Nature Reviews Gastroenterology & Hepatology, 2013, 10 (12) : 695 - 695
  • [46] Gemcitabine and nab-paclitaxel in patients with unresectable/borderline resectable pancreatic cancer.
    Thapaliya, P.
    Kundranda, M. N.
    Curtis, K. K.
    Callister, M. D.
    Ashman, J. B.
    Collins, J.
    Moss, A.
    Mekeel, K. L.
    Silva, A. C.
    Borad, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Safety and effectiveness of mirogabalin for CIPN induced by nab-paclitaxel in patients with pancreatic cancer
    Saito, Kei
    Nakai, Yousuke
    Ishigaki, Kazunaga
    Takahara, Naminatsu
    Suzuki, Tatsunori
    Hakuta, Ryunosuke
    Saito, Tomotaka
    Hamada, Tsuyoshi
    Mizuno, Suguru
    Kogure, Hirofumi
    Fujishiro, Mitsuhiro
    ANNALS OF ONCOLOGY, 2022, 33 : S520 - S520
  • [48] Nab-Paclitaxel for Metastatic Pancreatic Cancer: Clinical Outcomes and Potential Mechanisms of Action
    Al-Batran, Salah-Eddin
    Geissler, Michael
    Seufferlein, Thomas
    Oettle, Helmut
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 (03) : 128 - 134
  • [49] Nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreatic cancer: our experience
    Mare, M.
    Munao, S.
    Germana, S.
    Colarossi, C.
    Sciacca, D.
    Giuffrida, D.
    Giannone, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
    Ko, Andrew H.
    Truong, Thach-Giao
    Kantoff, Emily
    Jones, Kimberly A.
    Dito, Elizabeth
    Ong, Anna
    Tempero, Margaret A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (06) : 875 - 881
12345